Granuloma Annulare

Clinical guidelines for managing localized and generalized annular papules, evaluating palisading granuloma pathology, and reviewing topical and systemic immunomodulator treatments.

⏱️ 4 min read

Table of Contents

🧠 Standard of Care & Symptoms

Granuloma Annulare (GA) is a benign, chronic inflammatory skin condition characterized by papules arranged in a ring or annular pattern.

πŸ”¬ Diagnostics & Palisading Histopathology

Diagnosis is usually clinical but should be confirmed via biopsy to rule out tinea corporis (ringworm) or erythema annulare centrifugum.

Delayed Hypersensitivity & JAK-STAT Signaling

The granulomatous lesions of GA are the result of cell-mediated immune cascades targeting dermal tissues:

πŸ’Š Topical Steroids & Systemic JAK Inhibitors

Localized GA is often self-limiting, resolving spontaneously within 2 years. Treatment is initiated for cosmetic concerns or symptomatic lesions.

πŸ”¬ Active Clinical Trials

Clinical trials are currently evaluating topical and oral Janus Kinase (JAK) inhibitors, targeted PDE4 inhibitors, and monoclonal antibodies targeting tumor necrosis factor (TNF).

NCT06922466: Topical JAK1/JAK2 Inhibitor Cream

A Phase II trial evaluating a topical JAK1/JAK2 inhibitor cream for localized granuloma annulare.

Key Inclusion: Age ≥ 18, clinically and histologically confirmed localized Granuloma Annulare, affecting ≥ 2 separate anatomical areas, and willing to wash off other topical therapies.
NCT07050211: Oral Selective JAK3 Inhibitor

Testing the efficacy of an oral selective JAK3 inhibitor for widespread generalized granuloma annulare.

Key Inclusion: Age 18 to 75, biopsy-confirmed Generalized Granuloma Annulare with ≥ 10 active lesions across the body, and inadequate response to at least one systemic therapy (e.g. phototherapy or antimalarials).
NCT07119099: Target Subcutaneous Biologic Agent

Evaluating a novel subcutaneous biologic agent targeting macrophage activation pathways in treatment-resistant GA.

Key Inclusion: Age ≥ 18, severe recalcitrant localized or generalized GA, failed ≥ 2 standard treatments, and normal liver/renal function markers.
Important: Browse actively recruiting clinical trials in our Clinical Trials Catalogue to find a local study.

πŸ—ΊοΈ Next Steps After Diagnosis

If you have recently been diagnosed with Granuloma Annulare, follow these medical steps:

  1. Confirm the Diagnosis: Ensure your dermatologist has performed a skin biopsy if the ring does not respond to standard anti-fungal creams (to differentiate it from ringworm).
  2. Initiate Localized Steroids: Apply clobetasol under plastic wrap occlusion as directed to flatten symptomatic lesions on hands and feet.
  3. Screen for Diabetes: Request a routine HbA1c screening from your primary care physician, especially if you have widespread generalized lesions.
  4. Monitor for Spontaneous Efficacy: Localized rings often clear on their own without scarring; tracking lesions over 12 months is a viable management option.

❓ Patient FAQ

Q: Is granuloma annulare contagious? Can I spread it to other parts of my body?
A: No. Granuloma annulare is not an infection and is completely non-contagious. It cannot be spread to other people or to other parts of your body through contact. The lesions appear due to an internal immune reaction, not a fungus, virus, or bacteria.

Q: Why did my ringworm cream not clear this rash?
A: Ringworm (tinea corporis) is a fungal infection of the outer skin layer that looks very similar to granuloma annulare due to its ring shape. However, ringworm is typically scaly, itchy, and has a raised edge. Granuloma annulare consists of smooth, firm bumps under the skin with no surface scaling. Because GA is inflammatory rather than fungal, anti-fungal creams have no effect on it.

Get the Free 2026 Clinical AI Directory

Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.

Request Directory via Email